Functional modulation of IGF-binding protein-3 expression in melanoma

Journal of Investigative Dermatology

Volumn 130, Issue 8, 2010, Pages 2071-2079

  Dar, Altaf A ^a   Majid, Shahana ^b   Nosrati, Mehdi ^a   De Semir, David ^a   Federman, Scot ^a   Kashani Sabet, Mohammed ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEIN BAX; PROTEIN P21; PUMA PROTEIN; SOMATOMEDIN BINDING PROTEIN 3;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; NOVIKOFF HEPATOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; AZACITIDINE; BASE SEQUENCE; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN; DNA METHYLATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MELANOMA; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 77954757728     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.70     Document Type: Article

References (51)

1. Archer SY, Hodin RA (1999) Histone acetylation and cancer. CurrOpin Genet Dev 9:171-174
2. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
3. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168-174
4. Behrmann I, Wallner S, Komyod W et al. (2003) Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 163:683-690
5. Bender CM, Gonzalgo ML, Gonzales FA et al. (1999) Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 19:6690-6698
6. Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540
7. Buckbinder L, Talbott R, Velasco-Miguel S et al. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
8. Chang YS, Wang L, Liu D et al. (2002) Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8:3669-3675 (Pubitemid 35424756)
9. Chin L (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3:559-570
10. Christoph F, Weikert S, Kempkensteffen C et al. (2006) Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 119:13 9 6-402
11. Dar AA, Zaika A, Piazuelo MB, et al. (2008) Frequent overexpression of Aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112:1688-1698
12. De Mellow JS, Baxter RC (1988) Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156:199-204
13. Furuta J, Umebayashi Y, Miyamoto K et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95:962-968
14. Gonzalgo ML, Bender CM, You EH et al. (1997) Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336-5347
15. Guan X, Sagara J, Yokoyama T et al. (2003) ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer 107:202-208
16. Gucev ZS, Oh Y, Kelley KM et al. (1996) Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550
17. Gutgemann A, Golob M, Muller S et al. (2001) Isolation of invasion-associated cDNAs in melanoma. Arch Dermatol Res 293:283-290
18. Hanafusa T, Yumoto Y, Nouso K et al. (2002) Reduced expression of insulinlike growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176:149-158
19. Haqq C, Nosrati M, Sudilovsky D et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-6097
20. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054
21. Hoon DS, Spugnardi M, Kuo C et al. (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-4022
22. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787 (Pubitemid 30648894)
23. Ibanez de Caceres I, Dulaimi E, Hoffman AM et al. (2006) Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66:5021-5028
24. Kane MF, Loda M, Gaida GM et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811
25. Kristeleit R, Stimson L, Workman P et al. (2004) Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 9:135-154
26. Kusano M, Toyota M, Suzuki H et al. (2006) Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106:1467-1479
27. Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14(Spec No 1):R65-76
28. Le Marchand L, Kolonel LN, Henderson BE et al. (2005) Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14:1319-1321
29. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431
30. Majid S, Dar AA, Ahmad AE et al. (2009) BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30:662-670
31. Martin JL, Coverley JA, Pattison ST et al. (1995) Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136:1219-1226
32. Merlo A, Herman JG, Mao L et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1:686-692
33. Mirmohammadsadegh A, Marini A, Nambiar S et al. (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66:6546-6552
34. Moon JW, Chang YS, Ahn CW et al. (2006) Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int JCancer 118:353-356
35. Nakagawa T, Kanai Y, Ushijima S et al. (2005) DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression duringmultistageurothelial carcinogenesis. J Urol 173:1767-1771
36. Nosrati M, Li S, Bagheri S et al. (2004) Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin Cancer Res 10:4983-4990
37. Oh JS, Kucab JE, Bushel PR et al. (2002) Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 4:204-217
38. Oh Y, Muller HL, Lamson G et al. (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971 (Pubitemid 23206645)
39. Oy GF, Slipicevic A, Davidson B et al. (2010) Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int JCancer 126:350-361
40. Paz MF, Fraga MF, Avila S et al. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114-1121
41. Spugnardi M, Tommasi S, Dammann R et al. (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63:1639-1643
42. Tomii K, Tsukuda K, Toyooka S, et al. (2007) Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120:566-573
43. Tucker MA, Goldstein AM (2003) Melanoma etiology: where are we? Oncogene 22:3042-3052
44. Valentinis B, Bhala A, DeAngelis T et al. (1995) The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367
45. Wargo JA, Tanabe K (2009) Surgical management of melanoma. Hematol Oncol Clin North Am 23:565-581
46. Wiley A, Katsaros D, Chen H et al. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107:299-308
47. Worm J, Bartkova J, Kirkin AF et al. (2000) Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 19:5111-5115
48. Worm J, Christensen C, Gronbaek K et al. (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23:5215-5226
49. Xi Y, Nakajima G, Hamil T et al. (2006) Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther 5:3078-3084
50. Yu JZ, Warycha MA, Christos PJ et al. (2008) Assessing the clinical utility of measuring insulin-like growth factor binding proteins in tissues and sera of melanoma patients. JTransl Med 6:70
51. Zhou XP, Gimm O, Hampel H et al. (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am JPathol 157:1123-1128